title: No beta cell desensitisation after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes.
authors.forename: D
authors.initials: D
authors.lastname: Iafusco
authors.forename: C
authors.initials: C
authors.lastname: Bizzarri
authors.forename: F
authors.initials: F
authors.lastname: Cadario
authors.forename: R
authors.initials: R
authors.lastname: Pesavento
authors.forename: G
authors.initials: G
authors.lastname: Tonini
authors.forename: S
authors.initials: S
authors.lastname: Tumini
authors.forename: V
authors.initials: V
authors.lastname: Cauvin
authors.forename: C
authors.initials: C
authors.lastname: Colombo
authors.forename: R
authors.initials: R
authors.lastname: Bonfanti
authors.forename: F
authors.initials: F
authors.lastname: Barbetti
mesh_terms: D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000235:genetics*; D005905:Glyburide / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007231:Infant, Newborn; D009154:Mutation; D024661:Potassium Channels, Inwardly Rectifying / Q000235:genetics*; D000099161:Kcnj11 Channel
chemical_list: D005905:Glyburide; D007004:Hypoglycemic Agents; D024661:Potassium Channels, Inwardly Rectifying; D000099161:Kcnj11 Channel